Insights
Search Results
Client Highlights
12.08.25
Wilson Sonsini Advises Foresight Diagnostics on Acquisition by Natera
On December 5, 2025, Natera, Inc., a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, announced that Natera has completed its acquisition of Foresight in an all-stock transaction consisting of a $275 million upfront payment with an additional $175 million in earnouts tied to the achievement of revenue- and reimbursement-based milestones. Wilson Sonsini Goodrich & Rosati advised Foresight on the transaction.
The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.
The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.
Client Highlights
2.13.25
Wilson Sonsini Advises Junevity on $10 Million Seed Funding
On February 13, 2025, Junevity, a biotechnology company on a mission to extend lifespan and healthspan by resetting cell damage from age-related diseases, announced $10 million in seed funding led by Goldcrest Capital and Godfrey Capital. Wilson Sonsini Goodrich & Rosati advised Junevity on the transaction.
The Junevity RESET platform is based on exclusively licensed research by co-founder Dr. Janine Sengstack at the University of California at San Francisco. RESET uses large-scale human data and AI to identify genes—or transcription factors—that can regulate cell damage. Then, it develops siRNA therapeutics against these targets to return cells to health. Junevity will use this seed funding to enhance the RESET platform and develop its first therapeutic candidates in Type 2 diabetes, obesity, and frailty.
The Wilson Sonsini team that advised Junevity on the transaction included James Huie and James Kim.
For more information, please see Junevity’s news release.
The Junevity RESET platform is based on exclusively licensed research by co-founder Dr. Janine Sengstack at the University of California at San Francisco. RESET uses large-scale human data and AI to identify genes—or transcription factors—that can regulate cell damage. Then, it develops siRNA therapeutics against these targets to return cells to health. Junevity will use this seed funding to enhance the RESET platform and develop its first therapeutic candidates in Type 2 diabetes, obesity, and frailty.
The Wilson Sonsini team that advised Junevity on the transaction included James Huie and James Kim.
For more information, please see Junevity’s news release.
Client Highlights
11.26.24
Wilson Sonsini Advises Epic Cleantec on $12 Million Series B Funding
On November 21, 2024, Epic Cleantec (Epic), a leader in water reuse technology for the built environment, announced the close of its $12 million Series B funding round. The investment will accelerate the expansion of Epic’s pioneering water reuse and resource recovery solutions across a growing portfolio of projects, positioning Epic as one of the fastest-growing providers of water reuse systems for commercial and residential real estate globally. Recently ranked #1 on Fast Company’s Most Innovative Companies list (10-100 employees), Epic has successfully commissioned some of the first building-scale onsite reuse projects throughout the water-scarce U.S. West and will be the first to deploy onsite water reuse systems into high-rises in several major American cities across its national portfolio. Epic’s growing list of real estate and corporate clients includes notable names like Related, Salesforce, Crescent Heights, Westbank, Strada Investment Group, Alagem Capital, Kobayashi Group, and Stockdale Capital Partners.
Client Highlights
4.28.23
Wilson Sonsini Advises Foresight Diagnostics on $58.75 Million Series B
On April 27, 2023, Foresight Diagnostics, Inc, a leading developer of ultrasensitive cancer detection tests, announced the close of an oversubscribed Series B financing round of $58.75 million. The financing was led by Foresite Capital, with participation by Civilization Ventures, Bluebird Ventures, Pear Ventures, Agent Capital, Stanford University, and The University of Colorado Healthcare Innovation Fund. Wilson Sonsini Goodrich & Rosati advised Foresight on corporate, IP, licensing, and business advisory matters related to the transaction.
Client Highlights
1.19.23
Wilson Sonsini Advises SetPoint Medical on $80 Million Preferred Stock Financing
On January 19, 2023, SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced an $80 million preferred stock financing co-led by new investors Norwest Venture Partners and Viking Global Investors. New investor Gilmartin Capital also participated in the financing, along with returning investors New Enterprise Associates (NEA), Action Potential Venture Capital, Boston Scientific, Topspin Fund, Euclidean Capital, Morgenthaler Ventures, Richard King Mellon Foundation, ShangBay Capital, Ascendum Capital, Catalio Capital Management, Midas Capital, Citta Capital, SVE Capital, and an undisclosed strategic investor. Wilson Sonsini Goodrich & Rosati represented SetPoint Medical in the transaction.
Client Highlights
4.29.21
Wilson Sonsini Advises Ceribell on $53 Million Series C Financing
On April 29, 2021, Ceribell, innovator of the Rapid Response EEG™, a novel non-invasive brain monitor, announced the completion of a $53 million Series C financing, which was co-led by Longitude Capital and The Rise Fund. Other new investors include RA Capital Management, Redmile Group, and Red Tree Venture Capital, with additional support from existing shareholders. Wilson Sonsini Goodrich & Rosati represented Ceribell in the transaction.